Literature DB >> 21959597

Association of pretransplant serum phosphorus with posttransplant outcomes.

Marcelo S Sampaio1, Miklos Z Molnar, Csaba P Kovesdy, Rajnish Mehrotra, Istvan Mucsi, John J Sim, Mahesh Krishnan, Allen R Nissenson, Kamyar Kalantar-Zadeh.   

Abstract

BACKGROUND AND OBJECTIVES: Serum phosphorus levels are associated with mortality, cardiovascular disease, and renal function loss in individuals with and without chronic kidney disease. The association of pretransplant serum phosphorus levels with transplant outcomes is not clear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data of the Scientific Registry of Transplant Recipients (SRTR) up to June 2007 were linked to the database (2001 through 2006) of one of the U.S.-based large dialysis organizations (DaVita). The selected 9384 primary kidney recipients were divided into five groups according to pretransplant serum phosphorus levels (mg/dl): <3.5, 3.5 to <5.5 (reference group), 5.5 to <7.5, 7.5 to <9.5, and ≥9.5. Unadjusted and multivariate adjusted risks for transplant outcomes were compared.
RESULTS: Patients were 48 ± 14 years old and included 37% women and 27% African Americans. After multivariate adjustment, all-cause and cardiovascular death hazard ratios were 2.44 (95% confidence interval: 1.28 to 4.65) and 3.63 (1.13 to 11.64), respectively, in recipients in the ≥9.5 group; allograft loss hazard ratios were 1.42 (1.04 to 1.95) and 2.36 (1.33 to 4.17) in recipients with 7.5 to >9.5 and ≥9.5, respectively. No significant association with delayed graft function was found.
CONCLUSIONS: Pretransplant phosphorus levels 7.5 to <9.5 mg/dl and ≥9.5 mg/dl were associated with increased risk of functional graft failure and increased risk of all-cause and cardiovascular deaths, respectively, when compared with 3.5 to <5.5 mg/dl. Additional studies are needed to examine whether more aggressive control of pretransplant serum phosphorus may improve posttransplant outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959597      PMCID: PMC3359573          DOI: 10.2215/CJN.06190611

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  51 in total

Review 1.  Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure.

Authors:  Mario Cozzolino; Adriana S Dusso; Eduardo Slatopolsky
Journal:  J Am Soc Nephrol       Date:  2001-11       Impact factor: 10.121

2.  Post-transplant hypophosphatemia.

Authors:  M Levi
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

3.  Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus.

Authors:  Uyen Duong; Rajnish Mehrotra; Miklos Z Molnar; Nazanin Noori; Csaba P Kovesdy; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

Review 4.  Cardiovascular mortality in chronic renal failure: hyperphosphatemia, coronary calcification, and the role of phosphate binders.

Authors:  Richard A Fatica; Vincent W Dennis
Journal:  Cleve Clin J Med       Date:  2002       Impact factor: 2.321

5.  CKD-MBD: comfort in the trough of the U.

Authors:  John Cunningham; Justin Silver
Journal:  Nephrol Dial Transplant       Date:  2011-05-05       Impact factor: 5.992

6.  Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression.

Authors:  C Schwarz; G A Böhmig; R Steininger; G Mayer; R Oberbauer
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

7.  Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?

Authors:  Katherine Wesseling-Perry; Eileen W Tsai; Robert B Ettenger; Harald Jüppner; Isidro B Salusky
Journal:  Nephrol Dial Transplant       Date:  2011-03-25       Impact factor: 5.992

8.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

Authors:  Santhi K Ganesh; Austin G Stack; Nathan W Levin; Tempie Hulbert-Shearon; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

Review 9.  Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.

Authors:  G A Block
Journal:  Clin Nephrol       Date:  2000-10       Impact factor: 0.975

10.  Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals.

Authors:  Tohru Umekawa; Nasser Chegini; Saeed R Khan
Journal:  Nephrol Dial Transplant       Date:  2003-04       Impact factor: 5.992

View more
  10 in total

1.  Transplantation: Pretransplantation serum phosphorus level: association with mortality and graft survival.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2011-10-25       Impact factor: 28.314

2.  Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.

Authors:  Uyen Duong; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Joshua J Zaritsky; Isaac Teitelbaum; Csaba P Kovesdy; Rajnish Mehrotra
Journal:  Am J Nephrol       Date:  2012-01-26       Impact factor: 3.754

Review 3.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

4.  Mineral metabolism in European children living with a renal transplant: a European society for paediatric nephrology/european renal association-European dialysis and transplant association registry study.

Authors:  Marjolein Bonthuis; Marco Busutti; Karlijn J van Stralen; Kitty J Jager; Sergey Baiko; Sevcan Bakkaloğlu; Nina Battelino; Maria Gaydarova; Bruno Gianoglio; Paloma Parvex; Clara Gomes; James G Heaf; Ludmila Podracka; Dafina Kuzmanovska; Maria S Molchanova; Tatiana E Pankratenko; Fotios Papachristou; György Reusz; Maria José Sanahuja; Rukshana Shroff; Jaap W Groothoff; Franz Schaefer; Enrico Verrina
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-20       Impact factor: 8.237

Review 5.  Bone and mineral disorders after kidney transplantation: therapeutic strategies.

Authors:  Miklos Z Molnar; Mohamed S Naser; Connie M Rhee; Kamyar Kalantar-Zadeh; Suphamai Bunnapradist
Journal:  Transplant Rev (Orlando)       Date:  2013-12-12       Impact factor: 3.943

6.  Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes.

Authors:  Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Isidro B Salusky; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 8.237

7.  Association of pre-transplant blood pressure with post-transplant outcomes.

Authors:  Miklos Z Molnar; Clarence E Foster; John J Sim; Adam Remport; Mahesh Krishnan; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin Transplant       Date:  2013-12-24       Impact factor: 2.863

8.  Prediction of Nonadherence and Renal Prognosis by Pre-Transplantation Serum Phosphate Levels.

Authors:  Mineaki Kitamura; Yasushi Mochizuki; Satoko Kitamura; Yuta Mukae; Hiromi Nakanishi; Yuki Ota; Kumiko Muta; Hiroshi Yamashita; Yoko Obata; Takahisa Iwata; Masaharu Nishikido; Sachiko Kawanami; Miwa Takashima; Hitoshi Sasaki; Hideki Sakai; Hiroshi Mukae; Tomoya Nishino
Journal:  Ann Transplant       Date:  2019-05-10       Impact factor: 1.530

9.  Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS.

Authors:  Marcelo Barreto Lopes; Angelo Karaboyas; Brian Bieber; Ronald L Pisoni; Sebastian Walpen; Masafumi Fukagawa; Anders Christensson; Pieter Evenepoel; Marisa Pegoraro; Bruce M Robinson; Roberto Pecoits-Filho
Journal:  Nephrol Dial Transplant       Date:  2020-10-01       Impact factor: 5.992

10.  Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.

Authors:  Elani Streja; Wei Ling Lau; Leanne Goldstein; John J Sim; Miklos Z Molnar; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Kidney Int Suppl (2011)       Date:  2013-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.